Pulmonary Subtypes Exhibit Differential Global Initiative for Chronic Obstructive Lung Disease Spirometry Stage Progression: The COPDGene® Study.

K. Young, M. Strand, M. Ragland, G. Kinney, E. Austin, E. Regan, Katherine E. Lowe, B. Make, E. Silverman, J. Crapo, J. Hokanson
{"title":"Pulmonary Subtypes Exhibit Differential Global Initiative for Chronic Obstructive Lung Disease Spirometry Stage Progression: The COPDGene® Study.","authors":"K. Young, M. Strand, M. Ragland, G. Kinney, E. Austin, E. Regan, Katherine E. Lowe, B. Make, E. Silverman, J. Crapo, J. Hokanson","doi":"10.15326/jcopdf.6.5.2019.0155","DOIUrl":null,"url":null,"abstract":"Rationale\nWe classified individuals into pulmonary disease subtypes based on 2 underlying pathophysiologic disease axes (airway-predominant and emphysema-predominant) and their increased mortality risk. Our next objective was to determine whether some subcomponents of these subtypes are additionally associated with unique patterns of Global initiative for chronic Obstructive Lung Disease (GOLD) spirometry stage progression.\n\n\nMethods\nAfter accounting for intra-individual measurement variability in spirometry measures between baseline (Phase 1) and the 5-year follow up (Phase 2) of the COPD Genetic Epidemiology (COPDGene®) study, 4615 individuals had complete data that would characterize patterns of disease progression over 5 years (2033 non-Hispanic whites; 827 African Americans; 48% female). Individuals could express increased risk for mortality on one or both of the primary subtype axes (airway-predominant or emphysema-predominant) and thus they were further classified into 6 groups: high-risk airway-predominant disease only (APD-only), moderate-risk airway-predominant disease only (MR-APD-only), high-risk emphysema-predominant disease only (EPD-only), combined high-risk airway- and emphysema-predominant disease (combined APD-EPD), combined moderate-risk airway- and emphysema-predominant disease (combined MR-APD-EPD), and no high-risk pulmonary subtype. Outcomes were dichotomized for GOLD spirometry stage progression from Phase 1 to Phase 2. Logistic regression of the progression outcomes on the pulmonary subtypes were adjusted for age, sex, race, and change in smoking status.\n\n\nResults\nThe MR-APD-only group was associated with conversion from GOLD 0 to preserved ratio-impaired spirometry (PRISm) status (odds ratio [OR] 11.3, 95% confidence interval [CI] 5.7-22.1) and GOLD 0 to GOLD 2-4 (OR 6.0, 95% CI 2.0-18.0). The EPD-only group was associated with conversion from GOLD 0 to GOLD 1 (OR 2.4, 95% CI 1.2-4.6), and GOLD 1 to GOLD 2-4 (OR 2.6, 95% CI 1.0-6.9). Conversion between PRISm and GOLD 2-4 (31%-38%) occurred in both the APD-only and the MR-APD-only groups.\n\n\nConclusion\nDifferential conversion occurs from GOLD 0 to PRISm and GOLD 0 to GOLD 1 based on groups expressing airway-predominant disease or emphysema-predominant disease independently or in combination. Airway-predominant and emphysema-predominant subtypes are highly important in determining patterns of early disease progression.","PeriodicalId":10249,"journal":{"name":"Chronic obstructive pulmonary diseases","volume":"20 1","pages":"414-429"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"26","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic obstructive pulmonary diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15326/jcopdf.6.5.2019.0155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 26

Abstract

Rationale We classified individuals into pulmonary disease subtypes based on 2 underlying pathophysiologic disease axes (airway-predominant and emphysema-predominant) and their increased mortality risk. Our next objective was to determine whether some subcomponents of these subtypes are additionally associated with unique patterns of Global initiative for chronic Obstructive Lung Disease (GOLD) spirometry stage progression. Methods After accounting for intra-individual measurement variability in spirometry measures between baseline (Phase 1) and the 5-year follow up (Phase 2) of the COPD Genetic Epidemiology (COPDGene®) study, 4615 individuals had complete data that would characterize patterns of disease progression over 5 years (2033 non-Hispanic whites; 827 African Americans; 48% female). Individuals could express increased risk for mortality on one or both of the primary subtype axes (airway-predominant or emphysema-predominant) and thus they were further classified into 6 groups: high-risk airway-predominant disease only (APD-only), moderate-risk airway-predominant disease only (MR-APD-only), high-risk emphysema-predominant disease only (EPD-only), combined high-risk airway- and emphysema-predominant disease (combined APD-EPD), combined moderate-risk airway- and emphysema-predominant disease (combined MR-APD-EPD), and no high-risk pulmonary subtype. Outcomes were dichotomized for GOLD spirometry stage progression from Phase 1 to Phase 2. Logistic regression of the progression outcomes on the pulmonary subtypes were adjusted for age, sex, race, and change in smoking status. Results The MR-APD-only group was associated with conversion from GOLD 0 to preserved ratio-impaired spirometry (PRISm) status (odds ratio [OR] 11.3, 95% confidence interval [CI] 5.7-22.1) and GOLD 0 to GOLD 2-4 (OR 6.0, 95% CI 2.0-18.0). The EPD-only group was associated with conversion from GOLD 0 to GOLD 1 (OR 2.4, 95% CI 1.2-4.6), and GOLD 1 to GOLD 2-4 (OR 2.6, 95% CI 1.0-6.9). Conversion between PRISm and GOLD 2-4 (31%-38%) occurred in both the APD-only and the MR-APD-only groups. Conclusion Differential conversion occurs from GOLD 0 to PRISm and GOLD 0 to GOLD 1 based on groups expressing airway-predominant disease or emphysema-predominant disease independently or in combination. Airway-predominant and emphysema-predominant subtypes are highly important in determining patterns of early disease progression.
慢性阻塞性肺疾病肺量测定分期进展:COPDGene®研究
我们根据两种潜在的病理生理疾病轴(气道显性和肺气肿显性)及其增加的死亡风险将个体划分为肺部疾病亚型。我们的下一个目标是确定这些亚型的一些亚成分是否与全球慢性阻塞性肺疾病(GOLD)肺量测定分期进展的独特模式相关。方法:在考虑COPD遗传流行病学(COPDGene®)研究的基线(1期)和5年随访(2期)之间肺活量测量的个体内部测量变异性后,4615名个体拥有完整的数据,可以表征5年内疾病进展模式(2033名非西班牙裔白人;827名非裔美国人;48%的女性)。个体可在一个或两个主要亚型轴(气道显性或肺气肿显性)上表现出更高的死亡风险,因此可进一步分为6组:仅高风险气道显性疾病(apd)、仅中度风险气道显性疾病(mr - apd)、仅高风险肺气肿显性疾病(epd)、合并高风险气道和肺气肿显性疾病(联合APD-EPD)、合并中度风险气道和肺气肿显性疾病(合并MR-APD-EPD),以及无高风险肺亚型。结果分为GOLD肺活量测定从1期到2期的进展。根据年龄、性别、种族和吸烟状况的变化调整肺亚型进展结局的Logistic回归。结果仅mr - apd组与GOLD 0转化为保留比例受损肺量(PRISm)状态(比值比[OR] 11.3, 95%可信区间[CI] 5.7-22.1)和GOLD 0转化为GOLD 2-4(比值比[OR] 6.0, 95% CI 2.0-18.0)相关。纯epd组与GOLD 0到GOLD 1 (OR 2.4, 95% CI 1.2-4.6)和GOLD 1到GOLD 2-4 (OR 2.6, 95% CI 1.0-6.9)的转换相关。在APD-only组和MR-APD-only组中,PRISm和GOLD 2-4之间的转换(31%-38%)都发生了。结论GOLD 0向PRISm和GOLD 0向GOLD 1的差异转化是基于气道显性疾病或肺气肿显性疾病单独表达或联合表达的差异。气道显性和肺气肿显性亚型在确定疾病早期进展模式方面非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信